A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802

Autor: Casaretti R, Comella P, Carlomagno C, Maiorino L, Greco E, Russo A, Sanna G, Barzelloni ML, Massidda B, Formica V, Serci C, Defraia S, Palmieri G, Ionta MT

Publikováno v: Annals of oncology (Dordr., Online) (2015). doi:10.1093/annonc/mdv344
info:cnr-pdr/source/autori:Casaretti R, Comella P, Carlomagno C, Maiorino L, Greco E, Russo A, Sanna G, Barzelloni ML, Massidda B, Formica V, Serci C, Defraia S, Palmieri G, Ionta MT/titolo:A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802/doi:10.1093%2Fannonc%2Fmdv344/rivista:Annals of oncology (Dordr., Online)/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume

Background: EGFR overexpression occurs in 27-55% of gastroesophageal adenocarcinomas, and correlates with poor prognosis. We aimed to assess the efficacy and safety of the anti-EGFR antibody Panitumumab (PANIT) in addition to Oxaliplatin, 5-FU and Le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::6d8a9e3d4ade429d60f7b6d675e4389e
http://www.cnr.it/prodotto/i/340717

L08 - A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with Metastatic Gastric or Gastroesophageal Junction adenocarcinoma (VEGA trial). A multicenter Phase II SICOG trial 0802

Autor: Casaretti, R., Comella, P., Carlomagno, C., Maiorino, L., Greco, E., Russo, A., Sanna, G., Barzelloni, M.L., Massidda, B., Formica, V., Serci, C., Defraia, S., Palmieri, G., Ionta, M.T.

Publikováno v: In Annals of Oncology October 2015 26 Supplement 6:vi92-vi92

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.